Retaining Unsuppressed Patients in HIV Care During the COVID-19 Pandemic
  • CME

The DHHS guidance on managing care for persons with HIV during the COVID-19 pandemic recommends integrating telehealth and postponing routine visits. What does this mean for patients who are not stably suppressed? Here’s my experience.
David A. Wohl, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: August 14, 2020 Expiration: August 13, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply guidance on strategies to retain vulnerable patients in care during the COVID-19 pandemic

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
Theratechnologies Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader,  AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director, HIV Services
North Carolina Department of Correction
Raleigh, North Carolina

David A. Wohl, MD, has disclosed that he has received funds for research support from Gilead Sciences, Merck, and ViiV and consulting fees from Gilead Sciences, Janssen, Merck, and ViiV.

Staff

Tiffany Hensley-McBain, PhD

Scientific Director

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with HIV infection.

Goal

The goal of this activity is to improve clinicians’ awareness of management considerations related to the COVID-19 pandemic for clinicians providing care for persons with HIV infection.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 14, 2020, through August 13, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO commentary by Professor Don Smith on CROI 2021 data on ARV-associated weight gain and long-acting injectable ART

person default Don Smith, MD Released: April 20, 2021

Drs Monica Gandhi and Joseph Eron discuss next-line ART options for a heavily treatment-experienced patient with multiclass resistance .

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 19, 2021 Expired: April 18, 2022

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Clinical Care Options (CCO) commentary by Nelly Mugo, MD, on new data from Kenya on STI incidence and on PrEP uptake from CROI 2021

Nelly Mugo, MBChB, MMed, MPH Released: April 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue